Improving the Predictive Value of Preclinical Mouse Models of Pseudomonas aeruginosa Respiratory Infection to Evaluate Antibiotic Efficacy

Methods Mol Biol. 2024:2721:215-231. doi: 10.1007/978-1-0716-3473-8_15.

Abstract

Disease-specific animal models and treatment regimens are essential to optimize anti-Pseudomonas drug testing. Mouse models of acute and chronic P. aeruginosa infections provide valuable resources that mimic the initial and progressive bronchopulmonary infection typically observed in a wide range of patients - in hospital settings, with cystic fibrosis or chronic obstructive pulmonary disease. In this chapter, we will explain how mice can be treated using different administration routes in disease-specific models of P. aeruginosa respiratory infection. We will also describe methods used to evaluate multiple endpoints, including profiling of bacterial and host responses. The application of these procedures in disease-specific models is essential to optimize the efficacy of anti-P. aeruginosa treatments and provide an enhanced link between preclinical testing and clinical trials.

Keywords: Airway infection; Antibiotics; Drug administrations; Murine models; Pseudomonas aeruginosa; Treatment regimen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Disease Models, Animal
  • Humans
  • Mice
  • Microbial Sensitivity Tests
  • Persistent Infection
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa / physiology
  • Respiratory Tract Infections* / drug therapy

Substances

  • Anti-Bacterial Agents